Elicio Therapeutics ELTX
NASDAQ ELTX
$1.90 -0.04 (-2.06%)
At close: Oct 23, 2026 · 4:00 PM EDT

Elicio Therapeutics (ELTX) Gains from Sales and Divestitures (2022 - 2024)

Updated

Elicio Therapeutics' Gains from Sales and Divestitures was $3,000 in FY2024, compared with -$105,000 in FY2023.

Analysis

Elicio Therapeutics (ELTX) Gains from Sales and Divestitures (2022 - 2024) Analysis & Trends

  • Per Business Quant data, Gains from Sales and Divestitures in earlier years was -$105,000 in FY2023 and -$4,000 in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn
10 Elicio Therapeutics 36.66 Mn -40.96 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 3,000.00
Sep 30, 2023 -105,000.00
Jun 30, 2023 -1,000.00
Jun 30, 2022 -4,000.00
API Access

Elicio Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ELTX&period=max&api_key=YOUR_API_KEY